Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Citrate versus regional heparin anticoagulation for CRRT in ICU patients with acute kidney injury
ACTRN12612000765820Phase 4Recruiting
- Sponsor
- Dr. Matthew Brain
- Start
- Mar 2012
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of trisodium citrate, heparin and protamine in acute kidney failure (AKF) (2 arms), sponsored by Dr. Matthew Brain. Primary endpoints: Circuit survival and filter life, Safety endpoints and 1 more. Started Mar 2012; status: recruiting.
02
Drugs
trisodium citrateheparinprotamine
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on ACTRN12612000765820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000765820.